The MEK1/MEK2 inhibitor Trametinib has shown efficacy in mono-administration with a 20% ORR in patients with AML R/R [37], but combination studies with azacitidine and venetoclax (NCT04487106), with the MDM2i AMG232 (NCT02016729) have not shown improved responses, despite the rationale for synergism. This evidence concerns the gene MAP2K1 and acute myeloid leukemia.